Endocrinology · Medical Literature
Reassessing Radioactive Iodine Use After Thyroidectomy in Low-Risk Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.
Abstract
Radioactive iodine (RAI) therapy is often administered post-total thyroidectomy in patients with low-risk differentiated thyroid carcinoma, despite guidelines advising against its routine application. Evidence regarding the efficacy of RAI in reducing recurrence and improving survival in low-risk differentiated thyroid cancer (DTC) remains inconsistent. We conducted a systematic review and meta-analysis of observational studies and randomized clinical trials that compare RAI versus no RAI in low-risk DTC patients. Databases such as MEDLINE, Scopus, Cochrane Library, and Google Scholar were searched through December 2025. Outcomes included recurrence, recurrence-free survival, treatment response, biochemical markers, and side effects. We performed statistical analysis using Review Manager (RevMan) 5.4 with a random-effects model, reporting odds ratios (OR) with 95% confidence intervals, and significance set at p 1 ng/mL (OR 1.20, 95% CI: 0.00-342.55; p = 0.95), elevated thyroglobulin antibodies (OR 0.91, 95% CI: 0.38-2.16; p = 0.83), xerostomia (OR 5.63, 95% CI: 0.05-667.24; p = 0.48), and dysphonia (OR 0.96, 95% CI: 0.53-1.72; p = 0.88), were also not significantly different between groups, although estimates were not precise. The available randomized and observational evidence does not demonstrate a clear, clinically meaningful benefit of routine RAI ablation in patients classified as low-risk DTC. These findings should be interpreted with caution due to heterogeneity across studies, variability in outcome definitions, and the predominance of observational data.
Clinical relevance
Despite major society guidelines (ATA, ETA) recommending against routine radioactive iodine (RAI) ablation in low-risk differentiated thyroid cancer (DTC), real-world practice patterns reveal persistent overuse of this therapy post-total thyroidectomy. This systematic review and meta-analysis of 10 studies (n = 5,260) directly addresses the evidence gap by synthesizing both randomized and observational data on RAI efficacy and safety in a well-defined low-risk DTC population. Given the growing incidence of low-risk DTC and increasing emphasis on treatment de-escalation, these findings carry immediate relevance for endocrinologists, thyroid surgeons, and nuclear medicine specialists managing this cohort.
Key findings
1. No statistically significant difference in recurrence was observed between RAI and no-RAI groups (OR 0.66, 95% CI: 0.41–1.08; p = 0.10), suggesting RAI does not meaningfully reduce recurrence risk in low-risk DTC. 2. Five-year recurrence-free survival did not differ significantly between groups (OR 2.47, 95% CI: 0.63–9.62; p = 0.19), with wide confidence intervals indicating substantial imprecision in the estimate. 3. Excellent treatment response rates were equivalent between RAI and no-RAI cohorts (OR 1.00, 95% CI: 0.52–1.92; p = 1.00), providing no evidence of ablation benefit on biochemical or imaging response criteria. 4. Serum thyroglobulin > 1 ng/mL did not differ significantly between groups (OR 1.20, 95% CI: 0.00–342.55; p = 0.95), though the extremely wide confidence interval renders this estimate unreliable and inconclusive. 5. Elevated thyroglobulin antibody levels were not significantly different between RAI and no-RAI patients (OR 0.91, 95% CI: 0.38–2.16; p = 0.83), offering no support for RAI's role in clearing thyroglobulin antibody interference. 6. Adverse effects including xerostomia (OR 5.63, 95% CI: 0.05–667.24; p = 0.48) and dysphonia (OR 0.96, 95% CI: 0.53–1.72; p = 0.88) were not statistically significant between groups; however, the point estimate for xerostomia suggests a potentially clinically meaningful harm signal that was underpowered to detect.
Practice implications
Endocrinologists and multidisciplinary thyroid teams should use this meta-analysis to reinforce guideline-concordant practice: routine RAI ablation should not be offered to patients meeting low-risk DTC criteria (e.g., ATA low-risk: intrathyroidal, well-differentiated, ≤4 cm, no lymphovascular invasion, no metastases), as it confers no demonstrable benefit in recurrence, survival, or treatment response. In shared decision-making discussions, clinicians should explicitly communicate that RAI carries potential morbidity — including salivary gland toxicity (xerostomia signal OR 5.63, though not statistically significant) — without proven oncologic gain in this risk stratum, thereby supporting active surveillance or TSH suppression alone post-thyroidectomy. Future practice should await higher-quality RCT data with standardized outcome definitions, as the current evidence base is limited by heterogeneity (I² variability across outcomes), inconsistent risk classification, and a predominance of observational study designs.